Travere Therapeutics

Valuation Analysis

About the Company

Travere Therapeutics en bref

Travere Therapeutics (TVTX) is currently trading at 48,08 € with a market capitalization of 4,5 Md €. The 52-week range spans from 12,18 € to 48,81 €; the current price is 1.5% below the yearly high. Year-over-year revenue growth stands at +55.6%.

💰 Dividende

Travere Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent Travere Therapeutics (TVTX) au consensus : Achat Fort. L'objectif de cours moyen est de 49,44 €, soit un potentiel de +2.84% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 37,49 € à 61,02 €.

Travere Therapeutics : la thèse d'investissement en détail

Travere Therapeutics (TVTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 55.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 331.88% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 19.86% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 312.47x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The share is trading at 98% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (19.86%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Travere Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.